Dietary yeast beta 1,3/1,6 glucan supplemented to adult Labrador Retrievers alters peripheral blood immune cell responses to vaccination challenge without affecting protective immunity

Article

Author: Fries-Craft, Krysten ; Aldrich, Charles G ; Kilburn-Kappeler, Logan R ; Bobeck, Elizabeth A

AbstractYeast-derived 1,3/1,6 β-glucans may alter host immunity to produce robust and quickly resolved responses that align with companion animal health goals. In adult dogs, immunomodulation by yeast 1,3/1,6 β-glucans in extruded kibble diet have not been well documented. The study objective was to evaluate systemic immune responses in dogs fed kibble diets with two yeast 1,3/1,6 β-glucans doses before and after vaccine challenge. Twenty-four adult Labrador Retrievers were assigned to three dietary treatments consisting of a basal diet (control) supplemented with 0.012% or 0.023% (0.5 or 1×, respectively) yeast 1,3/1,6 β-glucan with equal sex representation within each treatment (8 dogs/diet). Animals were fed experimental diets for a 29-d acclimation period, after which baseline blood samples were collected before administration of a combination canine distemper virus, parvovirus, and adenovirus-2 vaccine. Blood samples were collected weekly for 21 d following vaccination with whole blood for CBC analysis, serum for titer and cytokine assays, and peripheral blood mononuclear cells (PBMC) isolated for flow cytometric immune cell profiling. Data were analyzed using the MIXED procedure with diet and timepoint fixed effects. Serum titer was analyzed by Kruskal–Wallis test (SAS 9.4; P ≤ 0.05). Prior to vaccination, β-glucan diets did not affect serum cytokines, antibody titer, or immune cell populations. In the first 7 d post-vaccination (dpv), PBMC CD21low B cells increased 36.5% to 58.1% in all groups but the magnitude of change was lesser in the 0.5× β-glucan diet resulting in 25.6% lower CD21low populations compared to control-fed dogs (P = 0.007). By 21 dpv, B-cell populations recovered to baseline levels in dogs fed 1× β-glucan, but CD21high cells remained elevated 50.5% in dogs fed 0.5× β-glucan diets compared with baseline (P < 0.0001). While no differences in serum titer or cytokines were observed, feeding both β-glucan diets maintained stable blood monocytes, whereas a 53.0% decrease between baseline and 14 dpv was observed in control-fed dogs (P = 0.01). Collectively, these outcomes suggest that a 1× dose of 1,3/1,6 yeast β-glucan in extruded kibble diets altered monocytes associated with trained immunity, did not reduce PBMC CD21low B-cell responsiveness, and simultaneously contributed to B-cell population resolution by 21 dpv in adult dogs. Additional research to assess the functionality of these changes is needed.

01 Jun 2012·Journal of Zoo and Wildlife MedicineQ4 · AGRICULTURAL & FORESTRY SCIENCE

HEMORRHAGIC AND NECROTIZING HEPATITIS ASSOCIATED WITH ADMINISTRATION OF A MODIFIED LIVE CANINE ADENOVIRUS-2 VACCINE IN A MANED WOLF (CHRYSOCYON BRACHYURUS)

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Julie Swenson ; Gregory A Bradley ; Kathryn Orr

A 15-yr-old, female, maned wolf (Chrysocyon brachyurus) was euthanized after presenting semicomatose with severe, uncontrolled frank hemorrhage from her rectum 6 days following a routine physical examination and vaccination. Histopathology indicated severe hemorrhagic and necrotizing hepatitis with intranuclear basophilic inclusion bodies in the liver that were thought to be consistent with adenoviral infection. Further classification by polymerase chain reaction, immunohistochemical staining, virus isolation, and electron microscopy confirmed the etiologic agent to be canine adenovirus-2. A representative sample of the vaccine that had been used was submitted and sequenced along with the virus isolated from the maned wolf. The sequencing of the etiologic agent that had been isolated from the maned wolf was determined to be the same as the strain of virus used in the production of the modified live vaccine that had been administered 6 days prior to death. From this information, the diagnosis of vaccine-induced adenoviral hepatitis was made. This is the first confirmed case of vaccine-induced canine adenoviral hepatitis in a maned wolf.

01 Jun 2009·Tropical Animal Health and ProductionQ3 · AGRICULTURAL & FORESTRY SCIENCE

Vaccination of chickens using raw rice coated with novel trehalose nano-organogels containing Newcastle disease (strain I-2) vaccine

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Wambura, P N

The formulation and evaluation of trehalose nano-organogels for storage and oral delivery of Newcastle disease (ND) strain I-2 vaccine to chickens were carried out in this study. Trehalose sugar was blended with vegetable oil to form nano-organogels where trehalose also acted as a stabilizer against thermal inactivation of I-2 ND virus. Results from infectivity titration assay indicated that the titre of 10(7.5) EID(50)/0.1 mL was maintained after 12 weeks of storage of nano-organogel I-2 vaccine at ambient room temperature. Serology results showed that 33% chickens which were vaccinated with nano-organogel I-2 vaccine after 14 days had HI antibody titres of > or = 3.0 log(2) with GMT of 2.3. Moreover, results showed 100% of chickens vaccinated with nano-organogel I-2 vaccine had the mean antibody titres of 3.4 and 3.7 log(2) at 21 and 28 days after vaccination, respectively. All vaccinated chickens (100%) survived the challenge of virulent ND virus whereas all unvaccinated chickens succumbed to challenge and died of signs consistent with ND. The findings from this study showed that the nano-organogel I-2 vaccine was stable at room temperature, safe and produced protective antibody response in vaccinated chickens. Moreover the nano-organogel I-2 vaccine was used for oral administration and hence is suitable for mass vaccination. However, optimization of the formulation of trehalose nano-organogel vaccine is required in order to achieve its application potentials.

100 Deals associated with HSV-2 vaccine (University of Queensland)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpesviridae Infections	Phase 2	-	The University of Queensland	-
Herpesviridae Infections	Phase 2	-	Admedus Vaccines Pty Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HSV-2 vaccine (University of Queensland)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation